Atherosclerosis
Volume 205, Issue 1 , Pages 227-232 , July 2009

Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: Results of the CEZAR study

  • Mir Abolfazl Ostad

      Affiliations

    • Department of Medicine II, Johannes Gutenberg-University Mainz, Germany
    • ,
  • Silke Eggeling

      Affiliations

    • University Heart Center, Department of Cardiology, Hamburg, Germany
    • ,
  • Peter Tschentscher

      Affiliations

    • University Hospital Hamburg-Eppendorf, Department of Clinical Chemistry, University of Hamburg, Germany
    • ,
  • Edzard Schwedhelm

      Affiliations

    • University Hospital Hamburg-Eppendorf, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Hamburg, Germany
    • ,
  • Rainer Böger

      Affiliations

    • University Hospital Hamburg-Eppendorf, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Hamburg, Germany
    • ,
  • Philip Wenzel

      Affiliations

    • Department of Medicine II, Johannes Gutenberg-University Mainz, Germany
    • ,
  • Thomas Meinertz

      Affiliations

    • University Heart Center, Department of Cardiology, Hamburg, Germany
    • ,
  • Thomas Munzel

      Affiliations

    • Department of Medicine II, Johannes Gutenberg-University Mainz, Germany
    • ,
  • Ascan Warnholtz

      Affiliations

    • Department of Medicine II, Johannes Gutenberg-University Mainz, Germany
    • Corresponding Author InformationCorresponding author at: II. Medizinische Klinik, Klinikum der Johannes Gutenberg-Universität Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany. Tel.: +49 6131 17 3746; fax: +49 6131 17 6428.

Received 19 September 2008 ,Revised 26 October 2008 ,Accepted 10 November 2008.

References 

  1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307
  3. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14:37–44
  4. Warnholtz A, Ostad MA, Heitzer T, et al. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease. Am J Cardiol. 2005;95:20–23
  5. Schwedhelm E, Tsikas D, Durand T, et al. Tandem mass spectrometric quantification of 8-iso-prostaglandin F2alpha and its metabolite 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2alpha in human urine. J Chromatogr B Biomed Sci Appl. 2000;744:99–112
  6. Frick M, Alber HF, Hugel H, et al. Short- and long-term changes of flow-mediated vasodilation in patients under statin therapy. Clin Cardiol. 2002;25:291–294
  7. Simons LA, Sullivan D, Simons J, et al. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis. 1998;137:197–203
  8. Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000;102:846–851
  9. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation. 2003;107:422–428
  10. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488–493
  11. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003;93:e98–103
  12. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104:376–379
  13. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415
  14. Settergren M, Bohm F, Ryden L, et al. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J. 2008;29:1753–1760
  15. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy. Eur Heart J. 2006;27:1182–1190
  16. Hognestad A, Aukrust P, Wergeland R, et al. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol. 2004;27:199–203
  17. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282–1288
  18. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2619–2624
  19. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am J Kidney Dis. 2004;43:589–599
  20. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356–2363

PII: S0021-9150(08)00846-0

doi: 10.1016/j.atherosclerosis.2008.11.032

Atherosclerosis
Volume 205, Issue 1 , Pages 227-232 , July 2009

Article Tools

* Image Usage & Resolution